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Abstract
Background: Mild parkinsonian signs (MPS) are common in the elderly population, and have been associated with vascular
diseases, mild cognitive impairment and dementia; however their relation to Parkinson’s disease (PD) is unclear.
Hypothesizing that individuals with MPS may reflect a pre-stage of PD, i.e. a stage in which the nigrostriatal system is
already affected although to a milder degree than at the time of PD diagnosis, aim of this study was to evaluate the
similarities between MPS and PD.
Methods: The TREND study is a prospective cross-sectional cohort study in individuals .50 years with biennial assessments
designed to identify markers for an earlier diagnosis of Parkinson’s and Alzheimer’s disease. For this substudy 992
individuals were included for analyses (892 controls, 73 MPS individuals, 27 PD patients). Parameters defining risk of PD (sex,
age, positive family history), prodromal markers (hyposmia, REM sleep behavior disorder, depression and autonomic failure)
as well as quantitative fine motor, axial motor and cognitive parameters were compared between the three cohorts.
Results: As expected, PD patients differed from controls with regard to 12 of 15 of the assessed parameters. MPS individuals
differed significantly from controls in 12 of the PD-associated parameters, but differed from PD only in 5 parameters.
Conclusion: This study shows that individuals with MPS share many prodromal and clinical markers of PD with PD patients,
implying that either a common dynamic process or similar constitutional factors occur in MPS individuals and PD patients.
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Introduction
Parkinson’s disease (PD) is characterized by the cardinal motor
features resting tremor, rigidity and bradykinesia. However, each
symptom individually as well as in combination is also highly
prevalent in elderly people who do not meet the criteria for
Parkinson’s disease (PD) [1] or other neurodegenerative diseases
[2–7]. Therefore they are referred to as mild parkinsonian signs
(MPS). MPS are associated with depression [8], hyposmia [9],
slight cognitive impairment [10] and dementia [11]. Moreover, in
individuals with MPS they are claimed to be a predictor for
mortality [12]. These symptoms are also known to occur as
‘‘prodromal markers’’ in Parkinson’s disease [13–15].
Up to now it is not entirely clear whether individuals with MPS
progress to a distinct neurological disease entity and if so, whether
they develop primarily PD, Alzheimer’s Disease (AD), vascular
parkinsonian syndromes or vascular dementia [16,17]. To solve
this issue, there are several studies focusing on the association of
MPS with the future development of dementia [3,5,7], but little is
known about the association with PD. If MPS, at least in a
subgroup of individuals, reflect a pre-stage of PD it must be a stage
in which the nigrostriatal system is already affected – i.e. an early
motor stage. Thus, assuming that the neurodegenerative process in
most PD patients indeed affects the central nervous system in an
ascending way, as first hypothesized by Braak et al. [18],
individuals with MPS should have a similar prodromal phase as
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PD patients and should also show deficits in Executive Function
(EF).
The aim of this study was to evaluate the similarities between
MPS and PD. Therefore we investigated the association of MPS
with risk factors, prodromal marker and early motor symptoms of
PD. To better quantify motor abnormalities we used accelerom-
eter based assessments and an automated device to quantitatively
assess fine motor tasks.
Subjects and Methods
Study population
For this analysis 1125 participants of the TREND study,
including eight individuals who had developed PD at the first
follow-up but had no Parkinsonism at baseline and 19 early-stage
PD patients from our outpatient clinic were included. The
TREND study (Tu¨binger evaluation of Risk factors for Early
detection of Neurodegenerative Disorders) is a prospective follow-
up study in individuals .50 years with biennial assessment until
death/autopsy. All participants were pre-screened via telephone
interview before study inclusion in 2009/10. Exclusion criteria
comprised a reported history of psychiatric diseases (other than
unipolar major depression), dementia, epilepsy, stroke, multiple
sclerosis, encephalitis and malignancies, intake of antipsychotics
and other drugs that may promote Parkinsonian symptoms. For a
detailed outline of the TREND study, inclusion and exclusion
criteria and baseline assessments see Berg et al.[19]. A large
assessment battery with mainly quantitative, unobstrusive mea-
surements designed to be repeated easily and objectively, is being
applied. Thus, with regard to neuroimaging only transcranial
sonography is applied to the whole cohort. More detailed
neuroimaging with more sophisticated techniques are carried out
in substudies in parts of the cohort, which, however, is not the
focus of this manuscript. All assessments are performed by a group
of experienced investigators. To make sure that there is no bias in
data acquisition all investigators are blinded to the results of all
other examinations.
Ethics Statement
The study was approved by the ethical committee of the
Medical Faculty of the University of Tu¨bingen (Nr. 90/2009BO2),
and all subjects gave written informed consent. To rule out
compromised capacity/ability to consent we asked participants for
known neurodegenerative diseases, including dementia in the pre-
screening.
Final sample
In total we investigated 1144 participants, of whom 27 had a
diagnosis of Parkinson’s disease, (median age 64 (41–83); 599
males and 548 females). To avoid an influence of additional
symptoms on the study outcome we had to exclude several
individuals: 51 participants who scored on the Beck Depression
Inventory (BDI) .18, as major depression is associated with
psychomotor slowness, 45 individuals with traumatic brain injury,
28 individuals who had a stroke within the first two years of the
study, 11 non-native speakers, seven with brain tumor, six with
Mini-Mental State Examination (MMSE),25 implying a demen-
tive process, three with negative delta Trail Making Test (TMT)
values (see below) and one with a secondary Parkinsonian
Syndrome. Thus 992 participants were finally analyzed (median
age 64 (41–83); 527 males and 465 females).
Neurological Examination
Each participant underwent a standardized neurological exam-
ination including the motor part of the Unified Parkinsons Disease
Rating Scale (UPDRS) by an experienced movement disorder
specialist [20]. For the diagnosis of MPS an abbreviated 10-item
version of the UPDRS was used [10]. The 10 items included
speech, facial expression, tremor at rest (in any body region),
rigidity (rated separately in the neck, right arm, left arm, right leg
and left leg), posture and body bradykinesia, with each item rated
from 0 to 4. A parkinsonian sign score (range= 0 to 40) was
calculated for each participant. MPS were defined as present when
any one of the following conditions was met: 1) two or more
abbreviated UPDRS ratings = 1 or 2) one abbreviated UPDRs
rating$2 or 3) an abbreviated UPDRS rest tremor rating = 1. PD
was diagnosed according to the UK Brain Bank clinical diagnostic
criteria.[1]
To minimize the variability in the UPDRS rating only raters
with several years of experience rated the participants.
Assessment of risk factors
Each participant underwent a structured medical interview
including demographics, medical history and medication.
A family history of PD was recorded according to the criteria of
Marder and colleagues [21]. A positive family history was stated to
be present if a family member showed at least three parkinsonian
signs (tremor at rest, shuffling gait, stooped posture, muscular
rigidity) or showed one of these signs and had one of the following:
general physician- or neurologist diagnosed PD or positive
response to levodopa.
Assessment of Prodromal markers
Impaired olfaction. Olfaction was tested using a 16 Sniffin’
sticks battery (BurghartMedizintechnik, Germany) as described by
Hummel et al. [22]. According to the suggestion of Hummel and
colleagues, less than 75% of correctly identified odours were
classified as abnormal (hyposmia).
Rapid eye movement sleep behaviour disorder
(RBD). Presence of possible RBD was determined by a self-
administered RBD screening questionnaire (RBDSQ).The
RBDSQ is a recently developed questionnaire, comprising 10
items to describe the most prominent clinical features of RBD
[23].
Depression. Depressive symptoms were measured by the
Beck Depression Inventory II (BDI) [24]. The BDI is a 21-item
self-report questionnaire, ranging from 0 to 60. Based on the BDI-
sum, a cut-off score for Major depressive disorder (MDD) was
defined as a BDI-score as .18.
Autonomic dysfunction. The Unified Multiple System
Atrophy Rating Scale (UMSARS) is a validated, disease-specific
scale assessing the diverse signs and symptoms in MSA [25]. In the
UMSARS part I motor functions of daily living and autonomic
functions are evaluated. For this study we built an UMSARS score
out of the autonomic questions 9 to 12. In these questions
orthostatic symptoms, urinary function, sexual function and bowel
function are assessed. Higher scores show more severe autonomic
dysfunction.
Accelerometer based exams. All subjects performed four
single task and two dual task trials. The four single tasks were: 1.
walking with habitual speed, 2. walking with maximum speed, 3.
checking boxes with maximum speed and 4. subtracting serial 7 s
with maximum speed. The two dual task trials were: 1. walking
with maximum speed and checking boxes with maximum speed.
2. walking with maximum speed and subtracting serial 7 s with
Mild Parkinsonian Signs in the Elderly
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maximum speed. All assessments were performed in an at least 1.5
meters wide corridor allowing obstacle-free 20 meter walks.






Formula 1: calculation of dual task costs
This formula gives information about the percentage of change
compared to the single task value. A positive value indicates a
decrease of speed. For detailed information see Hobert et al. [28].
Purdue PegBoard. A standard Purdue pegboard (Lafayette
Instruments, Lafayette, IN, USA) was used. Participants per-
formed three tasks: right hand, left hand and both hands. Each
task consisted of three 30 s trials with 20–30 s inter-trial intervals.
During the task, a participant had to pick single pegs from a well,
one at a time, using the thumb and index fingers of one hand, and
place them in specific holes on the pegboard (e.g. right hand, right
column beginning at the top). Subjects were encouraged to place
as many pegs as possible and the number of pegs placed on each
30 s trial was recorded. An average of number of pegs placed over
the three trials was calculated. Additionally a sum of scores (right
hand+ left hand+ both hands) was calculated and used for further
analyses.
Cognitive assessment. The TMT is a widely used paper-
and-pencil task that evaluates the executive functions cognitive
flexibility and working memory [29,30]. The TMT consists of two
parts: In TMT Part A subjects have to connect numbers from 1 to
25, which are randomly spread over a sheet of paper, in ascending
numerical order. In part B, participants are asked to connect
randomly spread numbers (from 1 to 13) and letters (from A to L)
in alternating numeric and alphabetical order (1-A-2-B-3-C-…-
13-L). In case of an error the examiner draws the attention of the
participant to the error, so that the participant completes the task
without errors (at the expense of additional time). The maximum
time allowed was 300 s. After this time the investigator discontin-
ued the experiment [31]. TMT performance was calculated taking
the time needed to perform TMT-B minus the time needed for
TMT-A. This delta TMT value prevents possible bias due to
differences in upper extremity motor speed, simple sequencing,
visual scanning, and psychomotor functioning [29,30].
Number of assessed parameters
In sum, we evaluated 15 parameters including risk factors (male
gender, positive family history of PD and age.60 years; n = 3);
prodromal markers (hyposmia, depression, possible RBD and
autonomic dysfunction; n= 4), quantitative motor markers (Pur-
due PegBoard, four different dual task cost parameters; n = 5) and
cognitive parameters (TMT part A, TMT part B and delta TMT
B-A; n= 3).
Statistics
Statistical analysis was performed using JMP10.0.0 (SAS). Due
to asymmetric distribution differences between the three groups
(Control, MPS and PD) were evaluated either with the Kruskal-
Wallis test for non-categorical data, or the chi-square test for
categorical data. Differences between two groups were investigated
by post-hoc Wilcoxon rank-sum test or by Fishers exact test.
Descriptive statistics are given either as median and range for non-
categorical data or as percentages for categorical data. Since age,
gender, MMSE and BDI were significantly different between the
groups and there were correlations between these factors and the
performance in motor and cognitive tasks we corrected them by
use of a logistic regression model, and assessed significance of each
model effect by the likelihood ratio. Differences were considered
significant at p,0.05.
Results
A final total of 992 persons were included in the analysis. MPS
were present in 73 (7.4%) participants. None of them fulfilled the
criteria of PD. Individuals with MPS were more often male (64%
vs. 52%; p,0.05), suffered more often from hyposmia (23% vs.
13%; p,0.05) or possible RBD (19% vs. 9%; p,0.01), had higher
depression and autonomic dysfunction scores than controls. With
regard to the prodromal markers we could show a correlation
between hyposmia and RBD (r=0.159, p,0.0001) (table 1).
Details of demographic and clinical variables are supplied in
table 2.
Individuals with MPS accomplished the TMT part A (38 s vs.
46 s; p,0.01) and part B (87 s vs. 105 s; p,0.05) faster than PD
patients. In contrast they were slower than controls only in the
more challenging TMT part B (80 s vs. 87 s; p,0.01) but not in
part A. However, assessing delta TMT values, individuals with
MPS needed more time than controls (43 s vs. 49 s; p,0.01) and
performed similar to PD patients. Finally PD patients had slower
results in all three TMT analyses compared to controls (p,0.01).
(Figure 1A-C)
Using the PurduePegBoard test, individuals with MPS and PD
patients were significantly slower than controls (HC: 40 pins, MPS:
37 pins, PD: 33 pins; each p,0.01). However, individuals with
MPS did not differ from PD patients with regard to speed.
(Figure 1D)
Under single tasking conditions, habitual walking speed,
maximum walking speed, and checking boxes speed individuals
with MPS performed worse than controls (each p,0.01). There
was no difference between the three groups (controls, MPS and
PD) in the subtracting task. (Figure S1A-D)
Under dual tasking conditions, checking boxes speed when
walking with maximum speed, maximum walking speed when
checking boxes and maximum walking speed when subtracting
serial 7 s individuals with MPS or PD performed worse than
controls p,0.01). There was no difference between individuals
with MPS or PD in these tasks. Analog to single tasking there was
no difference between the three groups under dual task condition
subtracting serial 7 s speed when walking with maximum speed.
(Figure 2A–D)
Dual task costs were not significantly different between the
investigated groups for checking boxes speed and for subtracting
serial 7 s speed. Dual task costs at maximum walking speed when
checking boxes and dual task costs at maximum walking speed
when subtracting serial 7 s were higher in individuals with MPS
and PD patients. Detailed data are shown in table 3.
In total PD patients differed from controls with regard to 12 of
the 15 parameters. MPS individuals also differed significantly from
controls in 12 of the PD-associated parameters, but differed from
PD only in five parameters.
In contrast to individuals with MPS or PD no difference could
be detected in individuals with RBD, depression or hyposmia with
regard to the UMSARS scores or the time needed for delta TMT
compared to controls without any of these prodromal markers.
Discussion
In this study we investigated whether individuals with MPS
show a similar pattern of prodromal markers as individuals with
PD.
Mild Parkinsonian Signs in the Elderly
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According to anatomical patterns of Lewy deposition in the
Braak staging system [18] we hypothezised that the prodromal
phase of PD is characterized by the occurrence of non-motor and/
or slight motor features which occur well before onset of typical
motor symptoms [15,32]. In the case of occurrence of both non-
motor and early motor symptoms, early motor symptoms emerge
often later than the non-motor symptoms [15,33,34] – suggesting
that the alterations in the nigrostriatal system follow alterations of
other (in general lower) parts of the nervous system (Figure 3). We
found that individuals with MPS, like PD patients, have a greater
frequency of depression, hyposmia, possible RBD and autonomic
dysfunction than controls. The association of MPS with depression
and hyposmia has been shown in previous studies [8,9]._EN-
REF_10_ENREF_35 The association with possible RBD reported
here is new to our knowledge and supports the association of MPS
with PD, as RBD is known to be the factor with the highest
relative risk of any currently known clinical marker for the future
development of the clinical phenotype of a synucleinopathy [33].
In addition to the non-motor prodromal features of PD we
found in individuals with MPS specific patterns of motor
impairment similar to the patterns observed in PD. With regard
to bradykinesia of fine motor skills, which is not included in the
diagnostic criteria for MPS although it is a central element of PD
diagnosis, both groups were equally slow and slower than controls.
In addition, we observed that individuals with MPS also walk
slower in the single walking tasks compared to controls. These
movement impairments may indicate an already affected nigro-
striatal system in individuals with MPS.
Impairment of executive function is an important marker for
prodromal PD, as it may be challenged under specific conditions
unrevealing a fragile system. Initially we used a more simple
cognition test: the TMT part A, which is a test for visual search
and motor speed skills. In this simple test and also in single task
subtracting serial 7s, individuals with MPS did not differ from
controls. More challenging tests like the TMT part B - which is a
test for complex visual scanning and cognitive flexibility – and the
delta TMT B-A revealed significant differences of individuals with
MPS and PD patients compared to controls. The same was found
for three of the four dual-task conditions. Especially in the latter
three conditions individuals with MPS performed at a level similar
to PD patients. In addition individuals with MPS and PD patients
showed higher dual task costs, which were driven by a
deterioration of the walking tasks but they performed as well as
controls in checking boxes and subtracting serial 7s tasks. This
may be explained by the following consideration: walking is not a
simple automatic function that is governed solely by subcortical
Table 1. Association between depression, hyposmia and possible RBD.
RBD Depression Hyposmia
RBD - 26%; r= 0.035 32%; r=0.159*
Depression 10%; r= 0.035 - 12%; r=20.026
Hyposmia 19%; r= 0.159* 19%; r=20.026 -
RBD, Rapid eye movement sleep behavior disorder; r, Spearmans Rho.
*p,0.001.
doi:10.1371/journal.pone.0092878.t001
Table 2. Demographic and clinical characteristics of participants.
Controls (n=892) MPS (n=73) Parkinson (n=27) p-value
Sex f/m 429/463 26/47* 10/17 0.07
age 64 (50–83) 67 (54–80)** 66 (41–80) 0.02
Education 13 (9–22) 13 (9–21) 13 (9–19) 0.18
MMSE 29 (25–30) 28 (25–30) 28 (26–30) 0.02
BDI 4 (0–17) 5 (0–17)* 7 (0–17)* 0.02
Hyposmia (%) 104 (13) 15 (23)* 6 (75)**{{a 0.001
possible RBD (%) 60 (7) 13 (19)** 4 (50)**{a 0.001
UMSARS Score 2 (0–10) 2 (0–8)** 4 (4–8)**{{ a 0.001
Orthostatic problems (%) 209 (24) 19 (27) 10 (37) 0.23
Urinary dysfunction (%) 331 (37) 38 (52)* 12 (44) 0.04
Sexual dysfunction (%) 447 (58) 49 (73)** 10 (100)**a ,0.01
Constipation (%) 124 (14) 13 (18) 7 (26) 0.16
Positive family history PD (%) 114 (13) 10 (14) 3 (11) 0.93
Positive family history AD (%) 226 (26) 11(16) 4 (15) 0.18
Values are presented as median (range) or as quantity (percentage).
BDI, Beck’s Depression Inventory; MMSE, Minimental State Examination; MPS, Mild Parkinsonian Signs; RBD, Rapid eye movement sleep behavior disorder.
a:Data not available of all PD patients due to incomplete questionnaire (8 out of 27).
p,0.05: * compared to controls; { compared to MPS.
p,0.01: ** compared to Controls; {{compared to MPS.
doi:10.1371/journal.pone.0092878.t002
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structures, it may constitute a much more complex task requiring
conscious attention and ongoing cognitive processing [35].
Therefore, slowdown in gait speed during dual task conditions is
natural because it reduces the risk of falls. It has been shown that
healthy individuals follow a posture first strategy [36,37]._EN-
REF_37_ENREF_37 Individuals with MPS and PD patients
suffer from cognitive inflexibility and therefore may have to slow
down their gait speed to a larger extend to achieve the desired
cognitive performance and avoid falls.
Taken together, our data from various tests suggest that
individuals with MPS, like PD patients, differ strikingly from
controls but share a substantial number of features with PD
patients. They share many risk factors and prodromal markers of
PD, suggesting that either a common dynamic process or similar
constitutional factors occur in MPS individuals and PD patients.
Because there were no associations in individuals with RBD,
hyposmia or depression with autonomic dysfunction or impaired
EF the effects detected in MPS seem not to be driven by additional
prodromal symptoms.
This is, to the best of our knowledge, the first study
demonstrating an association of MPS with PD not only in motor
features but also in risk and prodromal markers. However, not all
individuals with MPS will develop PD. Some may continue to
present MPS all their life, others may develop AD, other forms of
Lewy body diseases or a vascular neuropathology. Despite the
uncertain future of individuals with MPS, our study indicates that
they may form an important group for studying the prodromal
phase of neurodegenerative diseases. To better estimate which
combination of markers in individuals with MPS may indicate best
those who are in a process of neurodegeneration, finally leading to
clinical PD, AD or other neurodegenerative diseases, it is essential
to investigate individuals with MPS in prospective longitudinal
studies.
Figure 1. Trail Making test and Purdue PegBoard test results of Controls, individuals with MPS and Parkinson. A) TMT part A. B) TMT
part B. C) delta TMT B-A. PD patients were slower in all three TMT tasks compared with controls. Individuals with MPS need more time for completion
of TMT part B and in delta TMT B-A than controls but do not differ in the easier TMT part A. In the more complex tasks (B+C) PD patients and
individuals with MPS perform similar. D) sumscore of single right hand, single left hand and both hands: In the quantitative fine motor task individuals
with MPS as well as PD patients, perform slower than controls. MPS, Mild Parkinsonian Signs; PD, Parkinson’s Disease; TMT, Trail Making Test. *: p,
0.05; **: p,0.01
doi:10.1371/journal.pone.0092878.g001
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Limitations
A major limitation of this study is that the actual definition of
MPS does not include a separate rating of bradykinesia of finger/
hand movements which is an essential part in PD diagnosis. To
address this issue without changing the MPS definition by
including additional UPDRS items we evaluated finger/hand
movements with the Purdue Pegboard test and showed that MPS
is not only associated with whole body bradykinesia but also with
distinct bradykinesia finger/hand movements in an objective task.
Another limitation of this study is the diagnosis of RBD which
was made according to a questionnaire and not by polysomno-
graphy. Although the used questionnaire has high sensitivity and
Figure 2. Dual task results of Controls, individuals with MPS and Parkinson’s disease. Individuals with MPS and PD patients walk slower
and check fewer boxes under dual task conditions compared to controls. There is no speed difference between PD patients and individuals with MPS.
MPS, Mild Parkinsonian Signs; PD, Parkinson’s Disease *: p,0.05; **: p,0.01
doi:10.1371/journal.pone.0092878.g002
Table 3. Dual task costs.
Controls (n =892) MPS (n=73) Parkinson (n=27) p-value
Walking when checking boxes [%] 10.9 (2101.9–57.1) 14.3 (244.8–48.4)** 23.9 (216.0–49.0)**{{ ,0.001
Checking boxes when walking [%] 12.8 (294.2–70.6) 17.1 (32.1–52.4) 17.6 (241.9–65.2) 0.11
Walking when subtracting [%] 16.2 (272.6–66.5) 18.7 (249.6–57.5)a 24.3 (21.3–55.2)* 0.02
Subtracting when walking [%] 21.8 (2368.5–100) 20.7 (2175.7–91.3) 9.1 (2339.7–70.4) 0.89
MPS, Mild Parkinsonian Signs.
p,0.10: acompared to controls.
p,0.05: *compared to controls.
p,0.01: **compared to Controls; {{ compared to MPS.
doi:10.1371/journal.pone.0092878.t003
Mild Parkinsonian Signs in the Elderly
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specificity values [23] it is possible that there are some false
positives. We therefore used the term ‘‘possible RBD’’.
Furthermore this study is a crossectional analysis. Therefore,
these suggestive results have to be proven longitudinal follow ups
of this and other cohorts.
Supporting Information
Figure S1 Single task results of Controls, individuals
with MPS and parkinson. Individuals with MPS walk slower,
check fewer boxes per second and make fewer subtractions per
second than controls. MPS, Mild Parkinsonian Signs; PD,
Parkinson’s Disease. *: p,0.05; **: p,0.01.
(TIF)
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